CYTH — Cyclo Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $23.04m
- $34.29m
- $1.08m
Annual income statement for Cyclo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.01 | 0.903 | 1.59 | 1.38 | 1.08 |
| Cost of Revenue | |||||
| Gross Profit | 0.923 | 0.83 | 1.42 | 1.23 | 0.978 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.55 | 9.86 | 15.9 | 16.8 | 21.1 |
| Operating Profit | -7.54 | -8.96 | -14.3 | -15.5 | -20.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.53 | -8.94 | -14.3 | -15.5 | -20.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.82 | -5.59 | -2.24 | -1.85 | -1.23 |